Response of Children With Atopic Dermatitis (Eczema) to Eucrisa
Status:
Recruiting
Trial end date:
2021-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to develop biomarkers to predict what medication is best for
each child with atopic dermatitis (eczema). Participants will come in to Lurie Children's
Allergy of Dermatology clinic for a skin examination and complete surveys. They will apply
Eucrisa medication to their skin for 28 days before returning for a second and final skin
examination and complete surveys. During these skin exams, tape will be placed on the skin
and removed to collect skin cell samples. Photos will also be taken of the skin where tape
was placed. There is an optional blood draw.
Phase:
Phase 4
Details
Lead Sponsor:
Ann & Robert H Lurie Children's Hospital of Chicago